A s molecularly targeted cancer therapy improves, lineage plasticity is increasingly appreciated as a potential mechanism underlying therapeutic resistance. Lineage plasticity facilitates conversion of a cancer cell that is dependent on the therapeutic target to one that is indifferent to its function. For example, relapse of EGFR (epidermal growth factor receptor) mutant lung adenocarcinomas after EGFR-targeted therapy is associated with the appearance of histologically distinct variants that lack EGFR expression but express neuroendocrine lineage markers such as SYP (1, 2) . Likewise, prostate adenocarcinoma (PADC) relapsing from antiandrogen therapies (ADTs) is associated with histological variants exhibiting altered histology, reduced androgen receptor (AR) levels, and expression of neuroendocrine markers (3) (4) (5) . These neuroendocrine prostate cancer variants (NEPCs) emerge from PADC because they share clonal origin (5) (6) (7) (8) . The identification of effective therapies for NEPCs has been hindered by incomplete understanding of the mechanisms driving lineage plasticity and the lack of relevant experimental models.
The retinoblastoma tumor suppressor gene RB1 is more commonly mutated in metastatic and ADT-recurrent prostate cancer-NEPC variants in particular-than it is in primary tumors (5, (9) (10) (11) (12) . This suggests that there is selective pressure for RB1 loss during tumor evolution and that loss of this gene might drive PADC progression and lineage plasticity. To test this hypothesis, we engineered Rb1 deletion in a previously characterized mouse model of PADC initiated by Pten mutation (13) . In the original model, the PBCre4 transgene (14) is used to delete floxed Pten alleles specifically in prostate epithelium (fig. S1). PBCre4:Pten f/f mice, where f designates a floxed allele, develop prostatic intraepithelial neoplasia (PIN) by 6 weeks of age and invasive PADC by 9 weeks, but these cancers rarely progress to metastatic disease (13, (15) (16) (17) . Prostate cancer in PBCre4:Pten f/f :Rb1 f/+ mice is similar, so both genotypes are used interchangeably here and are referred to as single knockout (SKO). Rb1 mutation alone is insufficient to initiate prostate cancer development in the mouse because PBCre4:Rb1 f/f mice do not develop prostate cancer (18, 19) . The combination of these mutations in PBCre4:Pten f/f :Rb1 f/f (DKO) mice leads to prostate cancer development, and the mice had a significantly shorter median survival of 38 weeks compared with 48 weeks for SKO mice (Fig. 1A) . Rb1 loss did not affect end-stage tumor cell proliferation significantly, but similar to the loss of the tumor suppressor gene Trp53 (17), Rb1 loss abrogated the cellular senescence that occurs in Pten-deficient, premalignant prostate epithelium ( fig. S2 ).
End-stage SKO PADC showed expression of phosphorylated AKT (pAKT), nuclear AR, and the luminal epithelial marker Krt8 (Fig. 1B) . Expression of the basal epithelial marker Trp63 was low, and expression of the neuroendocrine marker Syp was undetectable. DKO PADC also showed expression of pAKT, but Krt8 and AR levels were heterogeneous between cells and regionally within contiguous tumors (Fig. 1B  and fig. S3A ). DKO PADCs also contained cells expressing Syp. Cells surrounding acini were Krt8 high :Syp low , whereas cells interspersed between acini were Krt8 low :Syp high ( fig. S3B ), suggesting the presence of at least two molecularly distinct cell populations within these tumors.
Metastasis was not detected in SKO mice, which is consistent with previous reports (15) (16) (17) . In contrast, distant metastasis was detected in all DKO mice examined to date (Fig. 1C) . Common metastatic sites were lymph node, lung, and liver. Bone metastasis was detected in 2 of 10 mice; this is likely an underestimate because we examined only a tibia and femur. All metastases recapitulated the heterogeneous Syp and Krt8 expression pattern of the primary tumors. Metastases disseminated through the vasculature because DKO cancer cells marked by green fluorescent protein (GFP) in PBCre4:Pten f/f :Rb1 f/f :Rosa mT/mG mice (20) were detected in both peripheral blood and bone marrow (Fig. 1, D (18) . However, the AR levels in DKO tumors are higher ( fig. S4D ), suggesting that they may be ADT sensitive. To test this, we surgically castrated 30-week-old, tumor-bearing DKO mice and monitored their survival. Castration extended median survival of DKO mice from 38 to 48 weeks ( Fig. 2A ), but all mice eventually died from prostate cancer by 67 weeks. The response of individual mice varied considerably, with postcastration survival ranging from 3 to 37 weeks, but survival did not correlate consistently with precastration total prostate volume (Fig. 2 , B and C). DKO cancer that relapsed after castration retained heterogeneous Krt8 and Syp expression but showed markedly reduced AR levels (Fig. 2D ). Bone metastasis was detected in three of eight mice with postcastration recurrent disease. We found that two of five postcastration recurrent cancers analyzed with RNAseq had acquired spontaneous Trp53 mutations (Fig. 2E) (Fig. 2F) . Metastasis to the lung, liver, and bone (one of four mice examined) was detected in TKO mice despite their short life span ( fig. S5A ). Castration of TKO mice at 10 weeks did not extend survival (Fig. 2G) , demonstrating that TKO PADC was ADT-resistant de novo. Primary TKO tumors showed patchy Krt8 and Syp expression like DKO tumors but had very low AR levels comparable with that of postcastration recurrent DKO tumors (Fig. 2H) . Surprisingly, pAKT levels were also reduced in TKO tumors despite uniform Pten loss ( fig. S5B ).
Thus, TKO tumors have reduced dependence on both AKT and AR signaling. We also examined young PBCre4:Pten cancer lineage plasticity underlying the development of ADT-resistant NEPC variants.
We next compared the gene expression patterns of SKO, DKO, and TKO tumors with that of normal prostate tissue. Gene expression patterns clustered primarily by genotype ( fig. S6A ). DKO and TKO tumors exhibited widespread changes in gene expression, encompassing~15% of mouse genes (Fig. 3A) . DKO and TKO tumors shared 85 to 90% of their differentially expressed genes. This similarity in gene expression between DKO and TKO tumors was not due to spontaneous silencing of Trp53 expression in DKO tumors (fig. S6B ). This implies that the primary driver of gene expression reprogramming in DKO and TKO tumors is Rb1 loss.
Consistent with immunostaining results, DKO and TKO tumors exhibited decreased levels of AR RNA and elevated levels of neuroendocrine lineage marker RNA (Figs. 1B and 2H and fig. S6C ). These changes are similar to those observed in human NEPC variants. To compare prostate cancer in these mouse models with the human disease, we used a weighted gene expression signature developed by Beltran et al. (5, 23) to distinguish human adenocarcinoma from NEPC variants. We found that SKO cancer was similar to human PADC, whereas DKO and TKO cancers were similar to human NEPC (Fig. 3B) . The Beltran signature accurately distinguishes SKO from DKO/TKO tumors through hierarchical clustering ( fig. S6D) .
Gene set enrichment analysis revealed that DKO and TKO tumors have altered expression of E2F target genes and neuroendocrine lineage genes (Fig. 3C) . We also noted altered expression of gene sets related to stem cells and epigenetic reprogramming, including increased expression of Sox2 [SRY (sex determining region Y)-box 2] and Ezh2 (histone methyltransferase enhancer of zeste homolog 2) (Fig. 3, D to F). Gene expression changes corresponding to stem cell reprogramming factors and neuroendocrine lineage markers were associated with a switch in posttranslational histone H3 modifications from the repressive H3K27me3 mark to the active H3K4me3 mark ( fig. S7 ). Human NEPC also exhibited increased expression of E2F target genes, neuroendocrine markers, stem cell reprogramming factors, and epigenetic regulators (Fig. 3G) . Thus, DKO and TKO prostate cancers mimic the molecular phenotype of human NEPC variants, and both human and mouse NEPC variants exhibit deregulation of stem cell reprogramming factors.
Rb1/E2f protein complexes can directly repress expression of Sox2 and Ezh2 (24, 25). We hypothesized that Rb1 loss in prostate cancer derepresses these genes, enabling epigenetic reprogramming toward a stem cell-like state. Lineage plasticity inherent in this state would facilitate metastasis, NEPC transformation, and ADT resistance. This hypothesis predicts that ADT resistance may be reversible through appropriate epigenetic modulation.
Ezh2 is the enzymatic component of the Polycomb Repressive complex 2 that methylates the lysine 27 residue of histone H3. Ezh2 inhibitors (Ezh2i) are being evaluated as cancer therapies in clinical trials. We isolated cell lines from mouse prostate cancers to test whether Ezh2i can restore ADT sensitivity in vitro. The cell lines behave like the tumors from which they were derived. For example, SKO, DKO, postcastration recurrent DKO (DKOCr), and TKO cell lines exhibit differences in AR expression, AR activity, neuroendocrine lineage marker expression, Ezh2 and Sox2 expression, cell proliferation, Ku and motility analogous to the behavior of their corresponding tumors in vivo ( fig. S8, A to G) . Enzalutamide sensitivity was highest in SKO cells, reduced in DKO cells, and lowest in cells from postcastration recurrent DKO (DKOCr) and TKO tumors ( fig. S8H) .
We tested two Ezh2 inhibitors (Ezh2i), GSK126 and EPZ6438, and found that they both sensitized TKO and DKOCr cells to enzalutamide when used at concentrations sufficient to inhibit histone H3K27 methylation but without significant single-agent cell growth inhibitory activity (Fig. 4, A to C, and fig. S9, A and B) . Ezh2i plus enzalutamide also had a greater effect on DKO cells than either drug as single agents ( fig. S9C) , and Ezh2i pretreatment inhibited DKO cell motility ( fig. S9E) S9D ), suggesting that its effects are specific for NEPC variants. We also evaluated the effects of Ezh2i in vivo. We propagated a primary DKOCr tumor by transplantation into SCID mice and then treated the mice with Ezh2i and enzalutamide, alone or in combination. Enzalutamide plus Ezh2i treatment slowed tumor growth significantly compared with treatment with enzalutamide [two-way analysis of variance (ANOVA) P = 0.037] or Ezh2i (P = 0.027) alone (Fig. 4D) . Enzalutamide treatment alone did not slow tumor growth relative to vehicle control (P = 0.43), confirming that the DKOCr tumor was ADT-resistant.
To genetically verify Ezh2 as the relevant target of Ezh2i, we silenced Ezh2 expression using short hairpin RNA (shRNA). Ezh2 silencing sensitized DKOCr cells to enzalutamide (Fig.  4, E and F) . Silencing Ezh2 also increased AR expression, augmented AR activity, increased expression of the luminal lineage marker Krt8, and decreased expression of neuroendocrine lineage markers (Fig. 4, F and G) . Ezh2i treatment also increased AR expression and decreased Syp expression in vitro (Fig. 4H) . Ezh2i-treated transplanted DKOCr tumors showed evidence of increased AR expression in vivo (Fig. 4I) , although immunostaining was patchy with both AR high and AR low regions present. These findings suggest that Ezh2i sensitizes NEPC variants to enzalutamide by reversing or suppressing lineage transformation.
To investigate whether Ezh2i has similar effects in human prostate cancer, we used LNCaP-AR cells from Mu et al. (26) in which RB1 and TP53 expression is stably silenced. Because LNCaP-AR cells were PTEN-null (27) , RB1-and RB1/TP53-silenced derivatives were analogous to DKO and TKO mouse cells, respectively. As in mouse cells, RB1 and RB1/TP53 silencing reduced AR levels and enzalutamide sensitivity, but enzalutamide sensitivity was restored by Ezh2i (Fig. 4J   and fig. S9F ). Thus, enzalutamide resistance is reversible in both human and mouse NEPC variants.
Rb1 and Trp53 repress epigenetic reprogramming factors such as Ezh2 and Sox2, which are important in generating induced pluripotent stem cells (24, 28, 29) . The data presented here support a hypothesis in which RB1 and TP53 loss in prostate cancer derepresses these same factors, creating a stem cell-like epigenetic environment permissive for lineage plasticity (Fig. 4K) . Lineage plasticity is proposed to drive prostate cancer progression by enabling adaptation to selective pressures experienced during metastasis and ADT. Because the mouse models characterized in this study develop metastatic PADC reminiscent of human NEPC variants, they will be useful for testing this hypothesis and identifying molecular mechanisms underlying cancer lineage plasticity. Our results also suggest a therapeutic approach to treat NEPC variants-that is, epigenetic modulation may reverse or delay lineage transformation, extending the durability of clinically beneficial ADT responses. As lineage plasticity is increasingly appreciated in other types of human cancers relapsing from molecularly targeted therapy, this approach may be generally applicable.
